Literature DB >> 26175410

Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer.

Wei Wei1, Michael J Birrer2.   

Abstract

Adaptive chemoresistance and consequent tumor recurrence present major obstacles to the improvement of the prognosis and quality-of-life of patients with advanced-stage ovarian cancer. In this issue of Cancer Cell, Yu and colleagues describe the critical role of spleen tyrosine kinase (SYK) in paclitaxel resistance by modulating the stability of microtubules.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26175410     DOI： 10.1016/j.ccell.2015.06.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  Protein Regulator of Cytokinesis PRC1 Confers Chemoresistance and Predicts an Unfavorable Postoperative Survival of Hepatocellular Carcinoma Patients.

Authors:  Yu Wang; Feng Shi; Guo-Hui Xing; Ping Xie; Na Zhao; Yu-Feng Yin; Shu-Yan Sun; Jing He; Ying Wang; Shi-Ying Xuan
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

2.  LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194.

Authors:  Jihong An; Weiling Lv; Yongzhou Zhang
Journal:  Onco Targets Ther       Date:  2017-11-10       Impact factor: 4.147

3.  Pygopus2 inhibits the efficacy of paclitaxel-induced apoptosis and induces multidrug resistance in human glioma cells.

Authors:  Cefan Zhou; Hongxia Cheng; Wenying Qin; Yi Zhang; Hui Xiong; Jing Yang; Huang Huang; Yefu Wang; Xing-Zhen Chen; Jingfeng Tang
Journal:  Oncotarget       Date:  2017-04-25

4.  LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a.

Authors:  Yunfei Duan; Jing Chen; Yu Yang; Zhen Qu; Yunjie Lu; Donglin Sun
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

5.  Expression of Syk and MAP4 proteins in ovarian cancer.

Authors:  Siwei Zhang; Suha Deen; Sarah J Storr; Anqi Yao; Stewart G Martin
Journal:  J Cancer Res Clin Oncol       Date:  2019-02-08       Impact factor: 4.553

6.  Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays.

Authors:  Mustafa A Barbhuiya; Manoj K Kashyap; Vinuth N Puttamallesh; Rekha Vijay Kumar; Xinyan Wu; Akhilesh Pandey; Harsha Gowda
Journal:  Oncotarget       Date:  2018-01-01

7.  Circular RNA circTNPO3 Regulates Paclitaxel Resistance of Ovarian Cancer Cells by miR-1299/NEK2 Signaling Pathway.

Authors:  Bing Xia; Zitong Zhao; Yinnayuan Wu; Ying Wang; Yan Zhao; Jing Wang
Journal:  Mol Ther Nucleic Acids       Date:  2020-06-08       Impact factor: 8.886

8.  Overexpression of kinesin family member 20A is associated with unfavorable clinical outcome and tumor progression in epithelial ovarian cancer.

Authors:  Han Li; Weijing Zhang; Xiaoying Sun; Jueming Chen; Yue Li; Chunhao Niu; Benke Xu; Yanna Zhang
Journal:  Cancer Manag Res       Date:  2018-09-12       Impact factor: 3.989

9.  The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.

Authors:  George E Duran; Branimir I Sikic
Journal:  PLoS One       Date:  2019-01-22       Impact factor: 3.240

10.  lncCRLA Enhanced Chemoresistance in Lung Adenocarcinoma That Underwent EpithelialMesenchymal Transition.

Authors:  Weili Min; Liangzhang Sun; Burong Li; Xiao Gao; Shuqun Zhang; Yang Zhao
Journal:  Oncol Res       Date:  2021-05-13       Impact factor: 5.574
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.